Wells Fargo analyst Brandon Couillard downgraded Myriad Genetics (MYGN) to Equal Weight from Overweight with a price target of $6, down from $22.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Reports Mixed Q1 2025 Results
- Myriad Genetics Faces Revenue Declines and Strategic Challenges: Hold Rating Maintained
- Myriad Genetics cuts FY25 adjusted EPS view to (2c)-2c from 7c-11c
- Myriad Genetics reports Q1 adjusted EPS (3c), consensus (5c)
- Myriad Genetics announces survey results on depression, anxiety